ACE2 and obesity disorder: Considering the current evidence, the employment of currently existing long used drugs should target SARS-CoV-2 infectivity, inflammatory response, or both, by addressing at least one of the following: ACE2 timing of expression in the lungs and balance between circulating and membrane-attached ACE2, enhancement of the angiotensin 1–7 axis, inhibition of TMPRSS2 actions, specific anti-inflammatory or immune-modulator effects, direct or indirect anti-viral activity, or blockage of harmful effects of dysfunctional RAAS overtly found in obesity.